Introduction GLOBOCAN 2008 [1] estimated that every year 493 243 women are newly diagnosed with cervical cancer and 273 505 die from the disease. Globally cervical cancer is the second most common cancer in women, but in developing countries it is the most common. Figure 1 shows the annual number of deaths from cervical cancer in developed and developing regions by age group, and it is evident that the number of deaths in developing countries is nearly 10 times greater than in developed countries.
In Africa, which has a population of 267.9 million women aged 15 years and older at risk of developing cervical cancer, approximately 80 000 women are diagnosed with cervical cancer per year, and just over 60 000 women die from the disease [1] . By comparison, in Europe, where there are 321.8 million women aged 15 years and older at risk, 59 931 women are diagnosed with cancer of the cervix and 28 812 die from the disease and cervical cancer ranks as the 7th most frequent cancer in Europe. America has a population of 336.5 million women aged 15 years and older and yearly 86 532 women are diagnosed with cervical cancer and 38 436 die from the disease. It ranks as the 4th most frequent cancer in women in America. Within continents, there is a significant variation in incidence of cervical cancer. Figure 2 shows the regional variation of incidence and deaths due to cervical cancer in Africa. Of note, is the very high incidence to mortality ratio of up to 80% in most regions except Southern Africa (57%).
The huge difference in cervical cancer incidence in developing vs. developed regions is a reflection of the absence of national cervical cancer screening programmes in most developing countries. Where national organized screening programmes have been implemented, as was achieved in many Scandinavian countries in the second half of the last century, cervical cancer incidence and mortality were significantly reduced [2, 3] . There are many barriers to setting up national screening programmes in developing countries, although in the last 15 Purpose of review This review is to inform the reader about the current situation with regard to treatment of cervical cancer in Africa and the barriers and complexities faced in most African countries. It also reviews the natural history of cervical cancer, the new 2009 International Federation of Gynecology and Obstetrics staging, and current treatment guidelines for cervical cancer.
Recent findings
There have been no dramatic new findings in the treatment of cervical cancer other than newer approaches to fertility-sparing surgery and the addition of concomitant chemotherapy to radiation for advanced cervical cancer and the data from randomized trials that have shown an improved overall and disease-free survival. The most important new findings in cervical cancer pertain to cervical cancer prevention strategies, which included using alternative approaches to cytology and the introduction of human papillomavirus (HPV) vaccination. Summary Cervical cancer is the commonest cancer cause of death among women in developing countries and efforts to prevent the disease using newer approaches and HPV vaccination should be implemented. Detection of cervical cancer at an early stage is associated with excellent survival but most women in developing countries present with advanced and often untreatable disease. The ratio between incidence and mortality from cervical cancer remains very high, largely due to lack of access to appropriate anticancer therapies in African countries. 
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Natural history of cervical cancer
The natural history of cervical cancer has been extensively studied in the past 30-40 years, and persistent infection of the cervix with certain high-risk types of human papillomavirus (HPV) has been well established as a necessary cause of cervical cancer. High-risk types of HPV are identified in nearly all carcinomas of the cervix and the relative risk of cervical cancer associated with infection with high-risk types of HPV is higher than the risk of lung cancer associated with smoking [4] . Munoz et al. [5] In a meta-analysis of HPV types found in invasive cervical cancers worldwide [6] data on a total of 10 058 patients (which included squamous cell carcinomas, adenocarcinomas, and adeno-squamous carcinomas) confirmed the high prevalence of HPV in cervical cancers in different regions of the world, with HPV 16 (51%) and 18 (16.2%) being the commonest. However, more than 16 other types of HPV were also associated with cervical cancer, of which types 45, 31, 33, 58, and 52 were the most prevalent. Further, HPV type 16 was more prevalent in squamous carcinomas and HPV type 18 more prevalent in adenocarcinomas of the cervix. Overall, HPV prevalence differed little between geographical regions (83-89%) but was low compared with the almost 100% prevalence in studies that have used the most sensitive methods of detection for HPV.
Cancer in AIDS Key points
Cervical cancer is the commonest cancer cause of death among women in developing countries where the ratio of incidence to mortality is close to 80%. Late presentation of disease with lack of access to diagnostic and anticancer therapies is the main cause of the very high mortality from cervical cancer in developing countries, particularly in Africa. Failure to implement secondary prevention cervical cancer programmes is widespread in Africa, due to competing health needs, gross deficiencies in trained healthcare professionals, poor health infrastructure, and widespread poverty. A more recent publication evaluated HPV infection in paraffin-embedded samples of histologically confirmed cases of invasive cancer from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania taken over a 60-year period [7 ] . Ten thousand five hundred seventy-five patients of invasive cervical cancer were included in the study and 85% (n ¼ 8977) were positive for HPV DNA. The eight most common types of HPV detected were 16, 18, 31, 33, 35, 45, 52, and 58 and their combined contribution to the 8977 positive cases was 91%. HPV types 16, 18, and 45 were the three most common types in each type of cervical cancer (squamous cell, adenocarcinoma, and adenosquamous carcinoma).
There is good evidence that HPV infection precedes the development of cervical cancer by a number of decades and that persistent infection with HPV is necessary for the development of and progression of precancerous lesions of the cervix, either to higher grades of precancerous disease or to cancer [8] . Cervical cancer progresses slowly over decades from preinvasive cervical intra-epithelial neoplasia to invasive cervical cancer, a process that can take 10-30 years.
Cervical cancer
Over 80% of the world's cases of cervical cancer are diagnosed in countries without screening programmes and in developed countries, the women who do develop cancer are either screen-detected or women who have not been screened. Most women in developing countries present with advanced disease, often untreatable or suitable only for palliation. At a large tertiary institution in Cape Town, between 1984 and 2000, 3098 women with cervical cancer were seen of whom 571 were stage II B (18%), 1425 were stage III A and B (46%), and 343 (11%) were stage IV (personal communication, Dr Leon Van Wijk, Department Radiation Oncology, Groote Schuur Hospital, Cape Town, South Africa). The revised International Federation of Gynecology and Obstetrics (FIGO) staging is shown in Table 1 . This staging has eliminated stage 0 (carcinoma-insitu), stage IIA has been sub-divided into IIA1 and IIA2 with a cut-off of 4 cm, as there are sufficient data to support that maximum tumor diameter has an impact on prognosis as it has in stage 1B cancer of the cervix [9] . Cervical cancer remains a clinically staged disease, largely because other means of staging are not available in many developing countries where the majority of cases are diagnosed. The use of diagnostic imaging to assess the size of the primary tumor is encouraged but not mandatory [10] . For those institutions with access to MRI/CT scanning, radiological tumor volume and parametrial extension should be recorded. Other investigations, for example, examination under anaesthesia, cytoscopy, sigmoidoscopy, and intravenous pyelography, are no long mandatory, but optional.
Understanding cervical cancer in the context of the African continent
Sub-Saharan Africa (SSA) consists of 52 countries almost all of which have the lowest ranked Human Development Index (HDI) and highest Human Poverty Indices (HPI) [12] .
Moreover, access to anticancer therapies is very limited in almost all African countries and a World Health Organization (WHO) study in 2001 found that only 22% of African countries had access to anticancer drugs, compared with 91% in Europe [14] . To illustrate the typical situation in Africa, Hanna and Kangolle [14] refer to the situation in Tanzania, which is a low-income country of 42.5 million people and where 21 180 new cases of cancer were diagnosed in 2008. Nationwide, there is one medical oncologist, four radiation oncologists, two physicists, and seven pathologists. There is no dedicated surgical oncology. There are two radiation machines in the country with an estimated need for 45.
The African continent has 130 medical schools located in 41 countries, but facilities for training in cancer diagnosis and management are found mainly in North Africa (Egypt, Morocco, Algeria) and South Africa with limited facilities in Nigeria, Libya, and Zimbabwe. In 2007, it was estimated that the per capita expenditure on health in the USA was $6096 compared with $32 in SSA, most of which were donor dollars [12] .
Further, there is a great shortage of trained healthcare personnel in Africa where there is also a very large 'brain drain' or exodus of trained personnel to other more attractive continents. The WHO estimated in 2006 that Africa has a needs-based shortage of 818 000 healthcare professionals (meaning doctors, nurses, and midwives) based on a country needing 2.28 healthcare professionals per 1000 population) [15] . In a study by Scheffler et al. [16] , they estimated that for 31 SSA countries in 2015, the shortage of healthcare professionals will be 792 000 and the estimated wage bill necessary to eliminate the shortage is approximately $2.6 billion.
Adding to the complexity of the challenges facing SSA (ranging from environmental disasters, to competing health needs, endemic civil strife, war, lack of safe water, and sanitation to name a few) has been the HIV/AIDS epidemic, where 70% of the world's cases of HIV are diagnosed (www.unaids.org). It has been well known that HIV infection increases the risk of developing certain cancers and Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer have been classified as AIDS defining diseases since 1993 [17] . Women infected with HIV have an increased risk of being infected with HPV and are therefore considered at higher risk for cervical cancer. However, the expected increase in women diagnosed with cervical cancer in Africa during the HIV pandemic has not been convincingly observed, most likely due to most at-risk women dying from other opportunistic infections prior to developing cervical cancer or its precursors. In the era of antiretroviral medication, this scenario is expected to change.
Studies have consistently shown higher prevalence of HPV infection, persistent infection with HPV, infection with multiple types of HPV, and higher prevalence of cervical cancer precursors in HIV infected women [18] [19] [20] . The Rwandan Women's Interassociation Study and Assessment (RWISA) is an observational prospective cohort study of 710 HIV positive women and 226 HIV negative Rwandan women, enrolled into the study in 2005 [21] . The prevalence of HPV was significantly higher in the HIV positive group and adjusted for age (25-34 years 75% vs. 29%; 35-44 years 64% vs. 7%; 45-54 years 57% vs. 13%, and over 55 years 38% vs. 0%). In addition 46% of HIV positive women had high-risk types of HPV and 35% were infected with multiple types and in turn, this was associated with higher risk of abnormal cytological findings.
Denny et al. [22] found that 68% of their cohort of HIV positive women were infected with high-risk types of HPV, and 94% of these infections persisted over a 36 month period, with only 6% clearing infections. In another South African study of 5595 women aged 35-65 years of age followed for 36 months, 577 women were HIV positive at enrolment and subsequently 123 women seroconverted. Among women who underwent HIV seroconversion, HPV prevalence was 20.3% before seroconversion, 23.6% at seroconversion, and 49.1% after seroconversion. HIV seroconversion was associated with newly detected HPV infection and increased risk of lowgrade cytological abnormalities compared with HIV negative women [23 ] . A recent article reported on a case controlled study from Cote d'Ivoire of 132 women with invasive cervical cancer and 130 control women who had normal pap smears. They found a positive association between HIV infection and women with cervical cancer and concomitant high-risk type of HPV infection with an OR of 3.4 (95% CI 1.1-10.8) [24] . The carcinoma is strictly confined to the cervix (extension to the corpus should be disregarded) The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous edema, as such, does not permit a case to be allotted to stage IV IVA Spread of the growth to adjacent organs IVB Spread to distant organs Adapted from [10, 11] . a All macroscopically visible lesions-even with superficial invasion-are allotted to stage 1B carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.0 mm and a horizontal extension of not greater than 7 mm. Depth of invasion should not be greater than 5 mm taken from the base of the epithelium of the original tissue-squamous or glandular. The depth of invasion should always be reported in millimeters, even in those cases with early (minimal) stromal invasion (1 mm). The involvement of vascular/lymphatic spaces should not change the stage. b On rectal examination there is no cancer-free space between the tumor and the pelvic side wall. All cases with hydronephrosis or nonfunctioning kidney are included, unless they are known to be due to another cause.
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Cervical cancer diagnosis and treatment in Africa
Cervical cancer has a range of presentations from asymptomatic screen detected microinvasive disease, to abnormal vaginal bleeding, malodorous vaginal discharge, pelvic pain or symptoms of more advanced disease such as vesico-vaginal or recto-vaginal fistulae or metastases (most commonly to lung, bone or liver). Cervical cancer spreads by direct invasion into the cervix, body of the uterus, vagina and parametrium, or by haematogenous or lymphatic permeation to distant sites. In most African countries women present with advanced disease and even in those countries with radiation facilities, survival is poor.
Treatment of early stage disease (stage 1 or stage 2a) is generally surgical unless there are contraindications to surgery, in which case primary radical radiation is the treatment of choice. Surgery ranges from a cone biopsy for early stage 1A disease to a radical hysterectomy (uterus, cervix, parametria, vaginal cuff) with bilateral pelvic lymph node dissection of external iliac, internal iliac, obturator, and common iliac lymph nodes). Increasingly fertility sparing surgery has been used in the surgical treatment of early stage disease, such as trachelectomy or radical trachelectomy for selected cases and with good results [25] but this type of surgery is generally not available in most African countries, nor is laparoscopic surgery.
Most women with cervical cancer in Africa will be treated with primary radiation therapy, either with curative or more commonly, palliative intent. On the basis of GLOBOCAN data from 2002, Barton et al. [26] estimated that 55% (range 47-61%) of new cases of cancer diagnosed in Africa had an indication for radiotherapy. Radiation facilities are not available at all in 15 African countries [27] . In those countries where radiation facilities do exist, there is usually one machine per several million people, for example, in Nigeria in 2007, there were only five radiation facilities for a population of over 150 million people [28] . In most cases, radiation is delivered using cobalt machines, which are a lot cheaper and easier to maintain than linear accelerators [26] . The median costs of radiotherapy using linear accelerators has been estimated at $11 compared with $4.87 for cobalt machines [29] . A survey of 72 low-income and middleincome countries found that 24 countries with populations greater than 1 million people did not have any radiotherapy service and the majority of these countries were in Africa [30] . Radiotherapy is still considered to be high technology medicine in Africa and where facilities do exist [e.g., South Africa, Ethiopia (one machine for a population of over 60 million), Madgascar, Nigeria, Tanzania, Uganda, Sudan, Kenya, Ghana, Senegal, Zimbabwe, Cameroon], they are located in tertiary institutions or in the private sector and are often nonfunctional or poorly maintained.
Radiation is an effective treatment for cervical cancer and randomized trials have shown a significantly improved survival with the addition of concomitant chemotherapy.
A meta-analysis of 15 trials involving 3452 women reported on survival when women were treated for cervical cancer with concomitant chemotherapy: the majority of trials used cisplatinum as the chemotherapeutic drug, and the minority used 5-fluorouracil, mitomycin C or a combination of both [31 ] . The review found that there was convincing evidence that adding chemotherapy to radiotherapy improves both overall survival and disease-free survival. Implementing this type of protocol in most African countries is unlikely to be feasible, even in South Africa, most units cannot afford to co-administer chemotherapy to women being treated with radiation for cervical cancer due to critical lack of resources.
Palliation for women with advanced disease is also extremely limited in most SSA countries, where for instance, oral morphine is only available in 11 countries [28] .
Conclusion
Cervical cancer is a preventable disease yet remains the commonest cause of cancer death among women in poor countries. Recent research into alternative approaches for the secondary prevention of cervical cancer offers new possibilities for more affordable and implementable programmes, particularly 'screen and treat' programmes that have been tested in randomized trials in South Africa and India and shown that HPV-based screening coupled with immediate treatment using cryotherapy significantly reduces both cervical cancer precursors and cervical cancer [32 ,33] . In addition to new approaches to secondary prevention of cervical cancer, the recent availability of two highly effective vaccines against HPV infection has major implications for future prevention: the bivalent vaccine targets HPV types 16 and 18 and the quadrivalent vaccine targets types 6 and 11 (responsible for genital warts) and types 16 and 18. Further, a great deal of current research is aimed at molecular detection of cervical cancer precursors, which should overcome many of the deficiencies associated with cervical cytology based screening and programmes.
A summit convened by the United Nations for September 2011 on noncommunicable diseases is likely to place the issue of cancer firmly on the agenda of health ministries, including those in Africa. It is hoped that providing adequate access to facilities for the diagnosis and treatment for African women will be made a priority.
